Capital International Investors Ascendis Pharma A/S Put Options Transaction History
Capital International Investors
- $557 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
280Shares Held
61.6MCall Options Held
202KPut Options Held
201K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.01 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.07 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$975 Million15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$867 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$833 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $10.9B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...